Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MOREWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MOREUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don’t find the answers you’re looking for, contact us for additional assistance.
EXPLORE MOREEach new vaccine is required to meet the strict standards issued by the European Medicines Agency (EMA) in order to be licensed. Creative Biolabs's primary serological assay allows our laboratory to test multiple strains of a single pathogen in combination with system and sample suitability controls to increase sensitivity and accuracy. Serological techniques commonly used for quantification include hemagglutination inhibition (HI), single radial hemolysis (SRH) and virus neutralization (VN) assays.
The HI assay is based on the ability of antibodies (if present in serum) to prevent agglutination between red blood cells and viral hemagglutinin. We use standard HI titers as a protective immune correlation according to FDA guidelines for vaccines.
Virus Neutralization (VN) is a useful diagnostic and basic research analysis that enables observation of humoral immune responses to viral vaccines. Compared to HI, the VN assay identifies multiple neutralizing antibodies, while HI only detects antibodies to viral hemagglutinin, which acts by preventing red blood cell agglutination.
Single tibial hemolysis (SRH) combines the advantages of single radial diffusion (SRD) and HI testing. This technique utilizes antibody diffusion within the gel to determine antibodies that may present in the serum of the assay. Hemolysis mediated by complement and induced by antibody-antigen complexes produces an easily identifiable "hemolysis zone" whose size is proportional to the concentration of anti-influenza antibodies present in serum.
For more details, please feel free to contact us for project quotations and more detailed information.
For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.
LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.
LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.
LEARN MORE
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE
